Vor Biopharma recently released its 10-Q report. The Boston-based clinical-stage biopharmaceutical company is focused on telitacicept, a fusion protein being developed for autoimmune diseases, including generalized myasthenia gravis, systemic lupus erythematosus, rheumatoid arthritis, Sjögren’s disease and IgA nephropathy. In June 2025, Vor in-licensed telitacicept from RemeGen and obtained rights to develop and commercialize it outside Greater China, while RemeGen kept rights in mainland China, Hong Kong, Macau and Taiwan.
In Item 2, management said the company had no revenue and continued to rely on financing to support development. Vor reported cash, cash equivalents and marketable securities of $466.1 million at June 30, 2026, and said it also raised $48.9 million in gross proceeds, before $0.5 million of commissions, from ATM sales after quarter-end. Based on its current operating plan, the company said that cash should fund operations and capital spending into early 2029.
The company reported a net loss of $62.8 million for the quarter ended June 30, 2026, compared with a net loss of $1.57 billion a year earlier. Operating expenses fell to $47.9 million from $274.3 million, driven mainly by the absence of the $222.6 million upfront expense tied to the telitacicept license that hit the prior-year quarter.
Research and development spending dropped to $25.9 million from $261.5 million. Within that total, telitacicept-related external spending was $12.2 million for gMG and $6.3 million for SjD, while other research and development costs fell to $1.9 million from $225.1 million. Salaries and benefits for R&D fell to $4.6 million from $11.7 million, and manufacturing, facilities and other research expenses declined to $0.1 million from $18.5 million.
General and administrative expense rose to $21.9 million from $12.8 million. Vor said the increase was mainly due to a $7.3 million rise in stock-based compensation, along with higher professional services and public-company costs. Interest income increased to $4.3 million from $0.5 million, while the change in fair value of warrant liabilities was a $19.3 million expense versus a $1.3 billion expense in the prior-year quarter.
For the first six months of 2026, Vor reported a net loss of $282.4 million, compared with $1.61 billion in the first half of 2025. The company ended the period with an accumulated deficit of $1.44 billion. Following these announcements, the company's shares moved -0.77%, and are now trading at a price of $23.19. Check out the company's full 10-Q submission here.
